CDC160: A Potential Drug Target and Biomarker for Cancer and Other Diseases

Target Name: CCDC160

NCBI ID: G347475

CCDC160

CDC160: A Potential Drug Target and Biomarker for Cancer and Other Diseases

CCDC160 (CC160_HUMAN), a protein that belongs to the superfamily of the leucine-rich repeat (LRR) proteins, is a potential drug target and biomarker for various diseases, including cancer. This protein is expressed in various tissues of the human body and has been shown to play a role in several cellular processes, including cell adhesion, migration, and invasion.

The CCDC160 protein is composed of 214 amino acid residues and has a calculated molecular weight of 21.9 kDa. It is expressed in various tissues of the human body, including the brain, heart, skeletal muscles, and placenta. It is also found in the extracellular matrix (ECM) of various tissues, including the ECM of cancer cells.

CDC160 has been shown to play a role in several cellular processes that are important for cancer progression. For example, it has been shown to promote the migration and invasion of cancer cells. In addition, it has been shown to contribute to the development of cancer stem cells.

CDC160 has also been shown to play a role in cell adhesion and signaling. For example, it has been shown to interact with the protein PDGFR-尾, which is a transcription factor that is involved in the development and progression of cancer. This interaction between CDC160 and PDGFR-尾 suggests that CDC160 may be a potential drug target for cancer.

In addition to its role in cancer, CDC160 has also been shown to play a role in several other cellular processes that are important for human health. For example, it has been shown to be involved in the development and progression of a variety of diseases, including neurodegenerative disorders, autoimmune diseases, and developmental disorders.

CDC160 has also been shown to have potential as a biomarker for several diseases. For example, it has been shown to be elevated in the blood of individuals with various neurological disorders, including Alzheimer's disease and Parkinson's disease. This suggests that CDC160 may be a potential biomarker for these disorders. It has also been shown to be elevated in the blood of individuals with certain autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. This suggests that CDC160 may be a potential biomarker for these diseases as well.

In conclusion, CCDC160 is a protein that has been shown to play a role in several cellular processes that are important for cancer progression and human health. As a potential drug target and biomarker, CCDC160 is a promising target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of CCDC160 in these processes and to develop effective treatments.

Protein Name: Coiled-coil Domain Containing 160

The "CCDC160 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC160 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets